{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-26-000043","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2026-06-22T20:16:44+00:00","discovered_at":"2026-06-22T20:18:00.341161+00:00","generated_at":"2026-06-22T20:18:19.344182+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Akebia shareholders approve increase in authorized shares from 375M to 525M","bullets":["Authorized common stock increased from 350M to 500M shares; total authorized capital from 375M to 525M.","Directors Adrian Adams, Michael Rogers, LeAnne Zumwalt elected as Class III for terms ending 2029.","Non-binding say-on-pay approved with 89.8M for vs 51.1M against; frequency vote favored annual (112.9M votes).","Ratification of Ernst & Young as auditor for FY2026 passed with 173.3M for vs 15.8M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-26-000043","json":"https://secwatch.observer/filing/0001517022-26-000043.json","markdown":"https://secwatch.observer/filing/0001517022-26-000043.md","text":"https://secwatch.observer/filing/0001517022-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/akba-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:18:19.344182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"010ebc40c3aa53477cc2037a580826127ce690a1","claim":"Akebia Therapeutics, Inc. shareholders approved Non-binding advisory recommendation on frequency of future advisory votes on executive compensation at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 4: The Company's stockholders recommended, on a non-binding advisory basis, that future advisory votes on the compensation of the Company's named executive officers be held every year. The results of the non-binding advisory vote on Proposal 4 were as follows: Votes for Every 1 Year Votes for Every 2 Years Votes for Every 3 Years Votes Abstaining 112,927,161 2,739,581 20,605,688 7,080,470","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"34396c7cde86c229ed6d847b47223173d1c15e2b","claim":"Akebia Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of capital stock and common stock at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 2: The Company's stockholders approved an amendment to the Company's Ninth Amended and Restated Certificate of Incorporation to (i) increase the number of authorized shares of capital stock from 375,000,000 to 525,000,000 and (ii) increase the number of authorized shares of common stock, par value $0.00001 per share, from 350,000,000 to 500,000,000 (the “Share Increase Amendment”). The results of the vote on Proposal 2 were as follows: Votes For Votes Against Votes Abstaining 102,504,108 88,853,129 293,594","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"3df67978d2a8f5ca4c7fad543b05531928eda289","claim":"Akebia Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 5: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote on Proposal 5 were as follows: Votes For Votes Against Votes Abstaining 173,306,165 15,754,273 2,590,393","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"6744b67e43c92f060f4f872208a8c2b3f533ed2f","claim":"Akebia Therapeutics, Inc. shareholders approved Election of Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 1: The Company's stockholders elected Adrian Adams, Michael Rogers and LeAnne M. Zumwalt as Class III directors, each to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal. The results of the vote on Proposal 1 were as follows: Votes For Votes Withheld Broker Non-Votes Adrian Adams 102,040,314 41,312,586 48,297,931 Michael Rogers 102,377,117 40,975,783 48,297,931 LeAnne M. Zumwalt 97,926,409 45,426,491 48,297,931","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"b91791d8801c9eb248363a54facdab0268c8ee49","claim":"Akebia Therapeutics, Inc. shareholders approved Non-binding advisory approval of named executive officer compensation at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 3 : The Company's stockholders' approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The results of the non-binding advisory vote on Proposal 3 were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 89,838,833 51,140,010 2,374,057 48,297,931","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/0001517022-26-000043-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}